Dissimilar survival and clinicopathological characteristics of mucinous adenocarcinoma located in pancreatic head and body/tail

BACKGROUND Growing evidence shows that pancreatic tumors in different anatomical locations have different characteristics,which have a significant impact on prognosis.However,no study has reported the differences between pancreatic mucinous adenocarcinoma(PMAC)in the head vs the body/tail of the pancreas.AIM To investigate the differences in survival and clinicopathological characteristics between PMAC in the head and body/tail of pancreas.METHODS A total of 2058 PMAC patients from the Surveillance,Epidemiology,and End Results database diagnosed between 1992 and 2017 were retrospectively reviewed.We divided the patients who met the inclusion criteria into pancreatic head group(PHG)and pancreatic body/tail group(PBTG).The relationship between two groups and risk of invasive factors was identified using logistic regression analysis.Kaplan-Meier analysis and Cox regression analysis were conducted to compare the overall survival(OS)and cancer-specific survival(CSS)of two patient groups.RESULTS In total,271 PMAC patients were included in the study.The 1-year,3-year,and 5-year OS rates of these patients were 51.6%,23.5%,and 13.6%,respectively.The 1-year,3-year,and 5-year CSS rates were 53.2%,26.2%,and 17.4%,respectively.The median OS of PHG patients was longer than that of PBTG patients(18 vs 7.5 mo,P<0.001).Compared to PHG patients,PBTG patients had a greater risk of metastases[odds ratio(OR)=2.747,95%confidence interval(CI):1.628-4.636,P<0.001]and higher staging(OR=3.204,95%CI:1.895-5.415,P<0.001).Survival analysis revealed that age<65 years,male sex,low grade(G1-G2),low stage,systemic therapy,and PMAC located at the pancreatic head led to longer OS and CSS(all P<0.05).The location of PMAC was an independent prognostic factor for CSS[hazard ratio(HR)=0.7,95%CI:0.52-0.94,P=0.017].Further analysis demonstrated that OS and CSS of PHG were significantly better than PBTG in advanced stage(stage III-IV).CONCLUSION Compared to the pancreatic body/tail,PMAC located in the pancreatic head has better survival and favorable clinicopathological characteristics.

Effect of antidepressants on body weight, ethology and tumor growth of human pancreatic carcinoma xenografts in nude mice

AIM: To investigate the effects of mirtazapine and fluoxetine, representatives of the noradrenergic and specific serotonergic antidepressant (NaSSA) and se- lective serotonin reuptake inhibitor (SSRI) antidepres- sant respectively, on body weight, ingestive behavior, locomotor activity and tumor growth of human pancre- atic carcinoma xenografts in nude mice. METHODS: A subcutaneous xenograft model of hu- man pancreatic cancer cell line SW1990 was estab- lished in nude mice. The tumor-bearing mice were ran- domly divided into mirtazapine group [10 mg/(kg·d)], fluoxetine group [10 mg/(kg·d)] and control group (an equivalent normal saline solution) (7 mice in each group). Doses of all drugs were administered orally, once a day for 42 d. Tumor volume and body weight were measured biweekly. Food intake was recorded once a week. Locomotor activity was detected weekly using an open field test (OFT). RESULTS: Compared to the fluoxetine, mirtazapine significantly increased food intake from d 14 to 42 and attenuated the rate of weight loss from d 28 to 42 (t = 4.38, P < 0.05). Compared to the control group, food intake was significantly suppressed from d 21 to 42 and weight loss was promoted from d 35 to 42 in the fluoxetine group (t = 2.52, P < 0.05). There was a significant difference in body weight of the mice after removal of tumors among the three groups. The body weight of mice was the heaviest (13.66 ± 1.55 g) in the mirtazapine group and the lightest (11.39 ± 1.45 g) in the fluoxetine group (F(2,12) = 11.43, P < 0.01). The behavioral test on d 7 showed that the horizontal and vertical activities were significantly increased in the mirtazapine group compared with the fluoxetine and control groups (F(2,18) = 10.89, P < 0.01). These effects disappeared in the mirtazapine and fluoxetine groups during 2-6 wk. The grooming activity was higher in the mirtazapine group than in the fluoxetine group (10.1 ± 2.1 vs 7.1 ± 1.9 ) (t = 2.40, P < 0.05) in the second week. There was no significant difference in tumor vol- ume and tumor weight of the three groups. CONCLUSION: Mirtazapine and fluoxetine have no effect on the growth of pancreatic tumor. However, mirtazapine can significantly increase food intake and improve nutrition compared with fluoxetine in a pan- creatic cancer mouse model.

Radical resection and outcome for malignant tumors of the pancreatic body and tail

AIM： TO analyze the factors influencing radical （R0） resection rate and surgical outcome for malignant tumor of the pancreatic body and tail. METHODS： The clinical and operative data and follow- up results of 214 pancreatic body and tail cancer patients were analyzed retrospectively. RESULTS： One hundred and twenty/214 pancreatic body and tail cancer patients underwent surgical treatment; the overall resection rate was 59.2% （71/120）, and the R0 resection rate was 40.8% （49/120）. Compared with non-R0 treatment, the patients receiving an R0 resection had smaller size tumor （P 〈 0.01）, cystadenocarcinoma （P 〈 0.01）, less lymph node metastasis （P 〈 0.01）, less peri-pancreatic organ involvement （P 〈 0.01） and earlier stage disease （P 〈 0.01）. The overall 1-, 3- and 5-year survival rates for pancreatic body and tail cancer patients were 12.7% （251197）, 7.6% （151197） and 2.5% （5/197）, respectively, and ductal adenocarcinoma patients had worse survival rates [15.0% （9/60）, 6.7% （4/60） and 1.7% （1/60）, respectively] than cystadenocarcinoma patients [53.8% （21139）, 28.2% （11139） and 10.3% （4139）] （P 〈 0.01）. Moreover, the 1-, 3- and 5-year overall survival rates in patients with RO resection were 55.3% （26/47）, 31.9% （15/47） and 10.6% （5/47）, respectively, significantly better than those in patients with palliative resection [9.5% （2/21）, 0 and 0] and in patients with bypass or laparotomy [1.2% （1/81）, 0 and 0] （P 〈 0.01）. CONCLUSION： Early diagnosis is crucial for increasing the radical resection rate, and radical resection plays an important role in improving survival for pancreatic body and tail cancer patients.

Pancreatic stents for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis should be inserted up to the pancreatic body or tail

AIM To investigate the location to which a pancreatic stent should be inserted to prevent post-endoscopic retrograde cholangiopancreatography(ERCP) pancreatitis(PEP).METHODS Over a ten-year period at our hospital, 296 patients underwent their first ERCP procedure and had a pancreatic stent inserted; this study included 147 patients who had ERCP performed primarily for biliary investigation and had a pancreatic stent inserted to prevent PEP. We dividedthese patients into two groups: 131 patients with a stent inserted into the pancreatic head(head group) and 16 patients with a stent inserted up to the pancreatic body or tail(body/tail group). Patient characteristics and ERCP factors were compared between the groups.RESULTS Pancreatic amylase isoenzyme(p-AMY) levels in the head group were significantly higher than those in the body/tail group [138.5(7.0-2086) vs 78.5(5.0-1266.5), P = 0.03] [median(range)]. No cases of PEP were detected in the body/tail group [head group, 12(9.2%)]. Of the risk factors for post-ERCP hyperamylasemia(≥ p-AMY median, 131 IU/L), procedure time ≥ 60 min [odds ratio(OR) 2.65, 95%CI: 1.17-6.02, P = 0.02) and stent insertion into the pancreatic head(OR 3.80, 95%CI: 1.12-12.9, P = 0.03) were identified as independent risk factors by multivariate analysis.CONCLUSION Stent insertion up to the pancreatic body or tail reduces the risk of post-ERCP hyperamylasemia and may reduce the risk of PEP.

Gastroesophageal Varices （Bleeding） and Splenomegaly： The Initial Manifestations of Some Pancreatic Body and Tail Carcinoma

INTRODUCTION The most common symptoms of the pancreatic body and tail carcinoma are epigastric pain, asthenia and back pain. However, these symptoms are nonspecific, which as a consequence leads to late diagnosis as well as a low resection rate between 10% and 30%, with a 5 years overall survival rate below 10%.

Schwannoma mimicking pancreatic carcinoma:A case report

BACKGROUND Schwannoma of the pancreas is extremely rare.We report a case of pancreatic schwannoma that was difficult to distinguish from pancreatic carcinoma before surgery.CASE SUMMARY A 66-year-old male underwent a right-lobe hepatectomy for hepatocellular carcinoma.Post-surgical computed tomography showed a 10 mm long solid mass with ischemia,with no expansion into the main pancreatic duct.Upon magnetic resonance cholangiopancreatography,the tumor had high signal intensity in diffusion weighted images,consistent with pancreatic carcinoma.Endoscopic ultrasound(EUS)was performed to obtain more information about the tumor,and showed a 14 mm solid and hypoechoic mass in the pancreatic body.Contrast enhanced EUS revealed that the tumor showed a hyperechoic mass in the early phase,and the contrasting effect continuation was very short;findings also consistent with pancreatic carcinoma.Thus,we preoperatively diagnosed his condition as a pancreatic carcinoma and performed distal pancreatectomy with splenectomy.Microscopic examination showed that the tumor was in fact a benign schwannoma.Histology showed a proliferation of spindle-shaped cell in a vague fascicular and haphazard pattern,with palisading arrangement.CONCLUSION Schwannoma of the pancreas is very rare,however,clinicians should consider schwannoma as the differential diagnosis for pancreatic tumors.

Prevention and treatment of pancreatic fistula after pancreatic body and tail resection: current status and future directions

Postoperative pancreatic fistula (POPF) is the most common and critical complication after pancreatic body and tail resection.How to effectively reduce the occurrence of pancreatic fistula and conduct timely treatment thereafter is an urgent clinical issue to be solved.Recent research standardized the definition of pancreatic fistula and stressed the correlation between POPF classification and patient prognosis.According to the literature,identification of the risk factors for pancreatic fistula contributed to lowering the rate of the complication.Appropriate management of the pancreatic stump and perioperative treatment are of great significance to reduce the rate of POPF in clinical practice.After the occurrence of POPF,the treatment of choice should be determined according to the classification of the pancreatic fistula.However,despite the progress and promising treatment approaches,POPF remains to be a clinical issue that warrants further studies in the future.

Reconstruction of the hepatic artery with the middle colic artery is feasible in distal pancreatectomy with celiac axis resection: A case report

Despite the advance of diagnostic modalities, carcinoma in the body and tail of the pancreas are commonly presented at a late stage. With unresectable lesions, long-term survival is extremely rare, and surgery remains the only curative option for pancreatic cancer. An aggressive approach by applying extended distal pancreatectomy with the resection of the celiac axis may increase the resectability and analgesic effect but great care must be taken with the arterial blood supply to the liver and stomach. Sometimes, accidental injury to the pancreatoduodenal artery compromises collateral blood flow and leads to fatal complications. Therefore, knowledge of any alternative restoration of the compromised collateral flow before surgery is essential. The present case report shows a patient with a pancreatic body cancer in whom the splenic, celiac, and common hepatic arteries were involved with the tumor, which extended almost to the root of the gastroduodenal artery. We modified the procedure by reanastomosis between the proper hepatic artery and middle colic artery without vascular graft. The postoperative course was uneventful, and the patient was discharged on post-operative day 19. The patient was immediately free of epigastric and back pain.

腹腔镜下根治性顺行模块化胰脾切除术与脻体尾切除术治疗胰体尾癌的效果分析

目的 分析腹腔镜下根治性顺行模块化胰脾切除术(LRAMPS)与脻体尾切除术(DPS)治疗胰体尾癌的效果。方法 选择该院2018年6月至2022年6月肝胆胰脾外科收治的86例胰体尾癌患者临床资料,根据患者所选术式不同分为LRAMPS组(40例)和DPS组(46例),比较两组手术情况、术后预后情况等。对两组随访至2022年12月,分析两组生存情况。结果 两组患者均顺利完成手术,住院期间无死亡病例。LRAMPS组术中出血量少于DPS组(P<0.05),术后24 h视觉模拟评分法(VAS)评分低于DPS组(P<0.05),R0切除率高于DPS组(P<0.05)。两组总有效率比较,差异无统计学意义(P>0.05)。对两组随访6~54个月,LRAMPS组复发率及肝转移率显著低于DPS组(P<0.05)。LRAMPS组术后中位生存期为18.5个月,DPS组为12.2个月,差异有统计学意义(P<0.05)。LRAMPS组术后18、24、36、48、54个月的存活率显著高于DPS组(P<0.05)。结论 DPS与LRAMPS治疗胰体尾癌的近期预后情况并无明显差异,但LRAMPS可减少患者术中出血量,减轻患者术后疼痛。在长期预后方面,LRAMPS较DPS治疗效果更佳,能有效延长患者生存期间,提高患者存活率,改善患者预后。

腹腔镜保留脾脏胰腺体尾部切除术治疗胰体尾良性肿瘤的效果及对术后并发症的影响

目的探讨腹腔镜保留脾脏胰体尾部切除术(LSPDP)治疗胰体尾良性肿瘤的效果及对术后并发症的影响。方法选取2014年3月至2021年3月新余市人民医院收治的78例胰体尾良性肿瘤患者作为研究对象,根据手术方式的不同分为观察组(n=46)与对照组(n=32)。观察组予以LSPDP治疗,对照组予以开腹保留脾脏的胰腺体尾部切除术治疗。比较两组手术相关指标(术中出血量、手术时间、术中输血次数、术后恢复情况(住院时间、肛门排气时间及首次进食时间)、疼痛程度[视觉模拟评分法(VAS)]、实验室指标[血清淀粉酶(AMS)、血小板(PLT)及白细胞(WBC)数目]及治疗期间并发症发生情况。结果观察组术中出血量少于对照组,肛门排气时间、首次进食时间及住院时间均短于对照组,差异有统计学意义(P<0.05)。术后2、4、6h,观察组VAS评分均低于对照组,差异有统计学意义(P<0.05)。治疗后,两组AMS、WBC、PLT水平均低于治疗前,差异有统计学意义(P<0.05),但两组间比较差异无统计学意义。观察组术后并发症发生率为15.22%,低于对照组的34.38%,差异有统计学意义(P<0.05)。结论腹腔镜下的保脾切除术有利于促进患者术后恢复,缓解患者术后疼痛,降低并发症发生率,值得临床推广应用。

胰腺脂肪含量及分布与2型糖尿病发生的关系

目的:应用磁共振Dixon技术测量胰腺脂肪含量,观察胰腺脂肪含量及脂肪分布对2型糖尿病(T2DM)发生的影响,并探讨胰腺脂肪含量及其分布情况对T2DM发生的预测价值。方法:回顾性分析147例接受腹部MRI和T1加权Dixon成像检查的病人,分为T2DM组59例、风险组病人38例及对照组50例,获得胰头、胰体、胰尾脂肪分数,收集病人的年龄、性别、吸烟及饮酒史、空腹血糖(FPG)、总胆固醇(TC)、高密度脂蛋白(HDL-C)、三酰甘油(TG)、低密度脂蛋白(LDL-C)、肝功能、血清肌酐(Cr)、体质量指数(BMI),比较各组数值差异。同时按BMI水平分为BMI正常组46例、超重组79例及肥胖组22例,分析T2DM组、风险组及对照组的胰腺各部位脂肪分数的差异。并进一步做logistic回归分析,以确定胰腺脂肪分布对T2DM发生的影响。结果:T2DM组、风险组与对照组之间的年龄、吸烟及饮酒比例、BMI、ALT、AST、Cr、TC、TG、HDL-C、LDL-C差异均无统计学意义(P>0.05)。3组病人的胰腺头、体、尾部及平均脂肪分数差异均有统计学意义(P<0.05~P<0.01),T2DM组的腺头、体和平均脂肪分数均高于对照组(P<0.05~P<0.01),T2DM和风险组胰尾的脂肪分数均高于对照组(P<0.01)。在BMI正常组中,T2DM组的胰头、体、尾及平均脂肪分数均为高于对照组(P<0.05);超重组中,T2DM组胰尾和平均脂肪分数高于对照组(P<0.05);在肥胖组中,3组不同部位及平均脂肪分数差异均无统计学意义(P>0.05)。多因素logistic结果显示,胰腺尾部的脂肪分数高是T2DM的独立危险因素(OR=1.685,95%CI:1.174~2.419,P<0.01),胰头、胰体脂肪分数、BMI、TC、TG及LDL-C水平与T2DM间关联无统计学意义(P>0.05)。结论:胰腺脂肪含量增加与T2DM相关,而胰尾脂肪含量的增加也会增加T2DM的发生风险。

胰体尾肿瘤的可视化仿真手术研究

目的研究可视化仿真手术在治疗中胰体尾肿瘤的应用。方法采集64排螺旋CT胰体尾肿瘤病人的原始扫描数据集,通过自适应区域生长算法对CT序列图像进行图像程序分割和自动提取,再采用自行研发的图像处理软件对图像数据进行三维重建,并导入FreeForm Modeling System进行图像修饰、平滑,然后利用GHOST SDK和PHANTOM软件系统进行胰体尾肿瘤病人术前的可视化仿真手术研究。结果三维重建后的胰腺、胰体尾部肿瘤与邻近脏器的三维结构清楚,主胰管、腹主动脉系统、门静脉系统、胆道等主要管道系统的分布、行程以及相互关系明晰。在胰体尾肿瘤的仿真手术系统中,利用GHOST SDK可以开发出来各种仿真手术器械,利用PHANTOM系统可以完成和真实手术一样的胰体尾肿瘤仿真手术,效果逼真。结论胰腺CT数据三维重建和可视化仿真手术的研究,对胰体尾肿瘤等胰腺手术的个体化手术方案制定、风险评估、临床教学训练等方面都有很大的应用价值。

保脾术式对胰体尾癌患者细胞免疫功能及预后的影响

目的探讨保脾术式对胰体尾癌患者细胞免疫功能及预后的影响。方法比较保留脾脏与切除脾脏的胰体尾癌术式的手术出血量、并发症发生率、患者细胞免疫功能、生存期。结果保脾组的术中出血量(240±70)ml明显少于切脾组(610±120)ml(t=-12.132,P=0.000);保脾组发生并发症2例,切脾组发生并发症6例,但2组并发症发生率无统计学差别(2χ=1.586,P=0.208)。保脾组中位生存期29.1月,切脾组中位生存期为22.4月,2组有统计学差异(2χ=3.942,P=0.043)。术后14 d保脾组CD3、CD4+显著高于切脾组[(61.08±4.80)%vs(56.03±2.56)%,t=4.172,P=0.000;(31.11±2.63)%vs(28.32±2.22)%,t=3.675,P=0.000],CD4+/CD8+、CD8+2组无统计学差异[(24.10±1.93)%vs(25.12±1.36)%,t=-1.909,P=0.064;(1.32±0.85)%vs(1.12±0.65)%,t=0.843,P=0.404]。结论保留脾脏的胰体尾切除术出血量少,术后患者免疫功能改善明显,生存期满意,适用于脾脏及脾动、静脉未受侵的胰体尾癌患者。

胰腺癌伽马刀和螺旋断层放疗治疗计划剂量学比较

选取14例胰腺癌病例,均用Tomotherapy和伽马刀两种治疗计划。通过DVH计算靶区剂量和周围要害器官剂量。得出伽马刀计划靶区剂量比Tomotherapy高,伽马刀可显著提高胰腺癌靶区剂量,减少周围正常组织剂量。Tomotherapy有很高的适形度,优于伽马刀,能很好控制十二指肠和胃的最高剂量,但低剂量区范围较大。

切割闭合器在胰体尾切除术中的应用

目的探讨切割闭合器(Endo-GIA stapler)在胰体尾切除术中应用的安全性及疗效。方法对2011年5月至2012年1月我院收治的胰体尾切除术患者资料进行回顾性分析。根据胰腺断端处理方法不同分成两组,一组采用Endo-GIA法,共30例,另一组采用手工缝合法,共80例;分别对两组手术时间、出血量、输血率、术后并发症、总住院费用等分析比较。结果两组患者手术均顺利完成,无围手术期死亡。两组患者手术时间、术中出血量、输血率,以及术后胰漏、腹腔出血、腹腔积液、腹腔感染等并发症发生率差别无统计学意义(P>0.05)。结论切割闭合器(Endo-GIA stapler)处理胰腺残端安全可靠,疗效明确。

胰腺癌伽玛刀和加速器治疗计划剂量学比较

目的:比较分析OUR-QGD型γ刀和两种加速器治疗技术胰腺癌治疗计划的剂量学数据,为临床选择放疗技术提供参考。方法:选取20例胰腺癌病例,每例设计靶中靶(Target in Target,TIT)、调强(IMRT)和γ刀三种治疗计划。处方剂量为50 Gy包绕95%的PTV。计算比较三种计划的PTV靶区适形指数和均匀性指数,通过DVH计算靶区剂量和周围要害器官剂量。结果:IMRT计划的PTV靶区适形度最好,TIT计划次之,γ刀计划最差,均匀性指数γ刀计划也要劣于IMRT和TIT计划,但γ刀计划周围正常组织的剂量相对较低,而靶区剂量比TIT和IMRT计划要高得多。结论:根据物理剂量学数据,γ刀治疗胰腺癌可显著提高靶区剂量,同时很好地保护周围正常组织;TIT和IMRT也是治疗胰腺癌的有效方法。

射频消融治疗不能切除的胰体尾癌

目的评估射频消融治疗不能切除的胰体尾癌的临床价值。方法对手术不能切除的10例胰体尾癌行术中射频热疗,观察并发症、近期疗效及生存情况。结果部分病例活检病理学报告为凝固坏死改变,术后CT为高密度改变,B超为高回声改变。所有病例均未并发胰瘘,术后腹痛明显缓解,术前8例CA19-9增高的患者术后明显下降。平均随访15个月,2例死亡,8例带瘤健康存活,生存质量尚可。结论RFA治疗不能切除的胰体尾肿瘤是安全的。

胰体尾癌70例临床病例分析

目的探讨分析胰体尾癌的诊治经验和影响预后的因素。方法回顾分析该院1995年9月～2005年8月收治的70例胰体尾癌的诊治情况,并于2008年4月对后5年的40例病例进行随访,采用Cox比例风险模型找出可能影响胰体尾癌预后的独立因素,用Kaplan-Meier方法和寿命表获得中位生存时间和1～5年生存率。结果94.3%的胰体尾癌病人在40岁以上,男女患者比例为1.59∶1,B超、CT和CA-199的检出率分别为86.0%、93.2%和81.0%;胰体尾癌的中位生存时间为(270±47)d,1～5年存活率分别为40.0%、17.5%、12.1%、3.0%和3.0%;Cox比例风险模型发现年龄、淋巴结肿大和治疗方式等变量是胰体尾癌的独立影响因素,其中根治性手术是改善胰体尾癌预后的关键且安全的,根治术后胰体尾癌的中位生存时间为490d,显著高于姑息治疗及无特殊治疗患者的195d。结论胰体尾癌易误诊,确诊时多属晚期;提高胰体尾癌的警惕,重视40岁以上男性的非特异性临床症状,联合应用影像学(B超、CT)和CA-199检查及早发现病情,积极予以根治治疗可有效改善胰体尾癌预后。

胰体尾优势供血动脉的数字减影血管造影

目的采用数字减影血管造影(DSA)方法,研究糖尿病患者胰体尾优势供血动脉的解剖特点,为临床胰腺介入治疗提供血管解剖依据。方法糖尿病患者108例,男61例,女47例,于介入治疗手术室行胰体尾动脉造影。第一阶段进行腹腔干、胃十二指肠动脉、肠系膜上动脉造影,初步定位胰尾体部优势供血动脉,之后将导管直接置入目标动脉,行DSA,观察胰体尾显影情况。如置入失败,则采用脾动脉远端球囊堵塞近端造影的方法,对胰体尾进行显影。保存介入影像进行分析。结果造影显示,胰体尾优势供血动脉分别为胰背动脉(58.3%,63/108)、胰大动脉(13.9%,15/108)、胰背动脉联合胰大动脉(11.1%,12/108)、胰横动脉(14.8%,16/108)和其他(1.9%,2/108)。优势动脉当中胰背动脉(共75例,胰背动脉单独63例,胰背联合胰大动脉12例)主要起源于脾动脉起始段(52.0%,39/75)、肝总动脉(21.3%,16/75)和肠系膜上动脉(24.0%,18/75)等;胰大动脉(共27例,胰背联合胰大动脉12例,胰大动脉单独15例)主要起源于脾动脉中段(96.3%,26/27);而胰横动脉主要起源于胃十二指肠动脉(68.8%,11/16)和胰十二指肠动脉(31.2%,5/16)等。结论胰体尾优势供血动脉的分布与起源存在较多变异情况,研究胰体尾部优势供血动脉有助于糖尿病患者胰腺介入治疗。

皮下置入药泵区域化疗在治疗不能切除的胰体尾癌中的初步应用

自１９９５年以来，对８例术中探查为不能切除的胰体尾癌进行皮下置入药泵及脾动脉置管，术后向药泵注入５Ｆｕ和ＭＭＣ，进行区域动脉化疗，并与１２例不能切除的胰体尾癌仅行外周静脉化疗的病例对照。结果显示，区域性动脉化疗组中位生存期７．０个月，静脉化疗组４．２个月，两组比较差异显著。本方法对延长不能切除胰体尾癌患者的生存期有较好疗效。